GlassScriptPhysician profile
Danielle Marie Olson-Basora
NPI 1891112819
$1,749.88
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $127 · 2021: $13.08 · 2022: $95.29 · 2023: $811 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.22 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.68 | 2023 | |
| Novo Nordisk INC | $208.52 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Astellas Pharma US INC | $194.70 | 2019-2023 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $146.22 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $145.45 | 2019-2023 | |
| Penumbra, INC. | $131.15 | 2024 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $111.02 | 2019-2023 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $109.23 | 2019-2020 | |
| Lilly USA, LLC | $100.01 | 2019-2023 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.34 | 2019-2020 | |
| Exact Sciences Corporation | $52.50 | 2023 | Cologuard Collection Kit |
| Alkermes, INC. | $46.21 | 2023 | Aristada, Lybalvi |
| Lundbeck LLC | $38.71 | 2022-2023 | Brintellix |
| Supernus Pharmaceuticals, INC. | $23.42 | 2019 | |
| Axsome Therapeutics, INC. | $20.52 | 2023 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.91 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.45 | 2023 | Givlaari |
| Orexo US, INC. | $14.58 | 2023 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.97 | 2019 | |
| Allergan, INC. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Olson-Basora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.